Abeona Therapeutics Inc.

LSE:0H7R Stock Report

Market Cap: US$279.4m

Abeona Therapeutics Valuation

Is 0H7R undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0H7R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0H7R ($6.46) is trading below our estimate of fair value ($322.68)

Significantly Below Fair Value: 0H7R is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0H7R?

Key metric: As 0H7R is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0H7R. This is calculated by dividing 0H7R's market cap by their current book value.
What is 0H7R's PB Ratio?
PB Ratio6.1x
BookUS$45.77m
Market CapUS$279.43m

Price to Book Ratio vs Peers

How does 0H7R's PB Ratio compare to its peers?

The above table shows the PB ratio for 0H7R vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average44.4x
BVXP Bioventix
16.4xn/aUK£197.0m
FARN Faron Pharmaceuticals Oy
152.8x17.3%UK£175.2m
PRTC PureTech Health
1.6x-13.0%UK£399.8m
OXB Oxford Biomedica
6.8x93.2%UK£451.5m
0H7R Abeona Therapeutics
6.1x61.8%US$279.4m

Price-To-Book vs Peers: 0H7R is good value based on its Price-To-Book Ratio (6.1x) compared to the peer average (45.4x).

Price to Book Ratio vs Industry

How does 0H7R's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.5x101.0%US$3.60m
VAL ValiRx
0.6xn/aUS$2.81m
No more companies available in this PB range
0H7R 6.1xIndustry Avg. 2.9xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0H7R is expensive based on its Price-To-Book Ratio (6.1x) compared to the UK Biotechs industry average (2.8x).

Price to Book Ratio vs Fair Ratio

What is 0H7R's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0H7R PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0H7R's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0H7R forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$6.46
US$16.75
+159.4%
25.5%US$21.00US$9.50n/a6
Nov ’25US$6.31
US$15.92
+152.2%
28.4%US$21.00US$7.50n/a6
Oct ’25US$6.38
US$15.92
+149.7%
28.4%US$21.00US$7.50n/a6
Sep ’25US$5.65
US$15.92
+181.5%
28.4%US$21.00US$7.50n/a6
Aug ’25US$4.80
US$16.42
+242.0%
29.7%US$21.00US$7.50n/a6
Jul ’25US$4.15
US$16.70
+302.9%
31.7%US$21.00US$7.50n/a5
Jun ’25US$4.34
US$16.70
+285.2%
31.7%US$21.00US$7.50n/a5
May ’25US$3.86
US$19.50
+405.2%
53.5%US$36.00US$8.00n/a4
Apr ’25US$7.18
US$21.00
+192.7%
43.4%US$36.00US$12.00n/a4
Mar ’25US$7.79
US$21.50
+176.0%
46.2%US$38.00US$12.00n/a4
Feb ’25US$4.30
US$21.50
+400.0%
46.2%US$38.00US$12.00n/a4
Jan ’25US$5.08
US$21.25
+318.7%
47.9%US$38.00US$11.00n/a4
Dec ’24US$4.85
US$21.25
+338.1%
47.9%US$38.00US$11.00n/a4
Nov ’24US$3.72
US$20.50
+451.8%
53.6%US$38.00US$8.00US$6.314
Oct ’24US$4.26
US$20.50
+381.7%
53.6%US$38.00US$8.00US$6.384
Sep ’24US$4.19
US$20.50
+389.3%
53.6%US$38.00US$8.00US$5.654
Aug ’24US$3.34
US$21.50
+543.7%
47.6%US$38.00US$10.00US$4.804
Jul ’24US$4.14
US$21.50
+418.9%
47.6%US$38.00US$10.00US$4.154
Jun ’24US$3.20
US$22.67
+608.3%
51.1%US$38.00US$10.00US$4.343
May ’24US$3.19
US$22.67
+610.6%
51.1%US$38.00US$10.00US$3.863
Apr ’24US$2.85
US$29.00
+919.3%
31.0%US$38.00US$20.00US$7.182
Mar ’24US$2.25
US$29.00
+1,187.7%
31.0%US$38.00US$20.00US$7.792
Feb ’24US$2.56
US$29.00
+1,033.3%
31.0%US$38.00US$20.00US$4.302
Jan ’24US$2.86
US$21.33
+645.1%
61.4%US$38.00US$6.00US$5.083
Dec ’23US$3.73
US$21.33
+471.7%
61.4%US$38.00US$6.00US$4.853
Nov ’23US$4.60
US$15.67
+240.7%
48.4%US$22.00US$5.00US$3.723

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$81.2b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$753.98

7D

0.6%

1Y

-8.0%

Formycon

€882.8m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€50.00

7D

7.5%

1Y

-24.1%

hVIVO

UK£146.3m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.21

7D

-6.1%

1Y

3.4%